OBiO anuncia una alianza estratégica con Refreshgene para comercializar un producto de terapia génica

Posted on by

Visite OBIO en el 30º Congreso Anual de la ESGCT en Bruselas SHANGHÁI, 24 de octubre de 2023 /PRNewswire/ — OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), organización líder mundial en desarrollo y fabricación por contrato para terapia celular y génica, ha anunciado…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.